Behçet's disease (BD) is a chronic inflammatory disease affecting multiple organ systems, such as the skin, joints, blood vessels, central nervous system, and gastrointestinal tract. Intestinal BD is characterized by intestinal ulcerations and gastrointestinal symptoms. The medical treatment of intestinal BD includes corticosteroids and immunosupressants. There have been several reports of tumor necrosis factor-α (TNF-α) blockers being successful in treatment of refractory intestinal BD. Here, we report on a patient who was diagnosed with intestinal BD despite treatment with the fully humanized TNF-α blocker (adalimumab) for underlying ankylosing spondylitis. This patient achieved clinical remission and complete mucosal healing through the addition of a steroid and azathioprine to the adalimumab regimen.
INTRODUCTION
Behçet's disease (BD) involves multiple organ systems, such as the skin, joints, blood vessels, central nervous system, and gastrointestinal (GI) tract [1] . Intestinal BD is characterized by intestinal ulcerations and gastrointestinal symptoms [2] . The incidence of BD involving the GI tract varies by country, ranging from 3% to 60% of cases of BD [3] . GI bleeding and perforation can be associated with intestinal BD, with resultant comorbidities [1] . The medical treatment for intestinal BD includes corticosteroids and immunosupressants. Unfortunately, surgical treatment, such as ileocecal resection, is sometimes necessary for intestinal BD with perforation, intractable pain, and hemorrhage which are refractory to conventional therapy [4] . There have been several reports of tumor necrosis factor-α (TNF-α) blockers being successful in refractory intestinal BD. Most of these reported on the efficacy of infliximab [4] [5] [6] [7] [8] [9] and a few reported on the efficacy of adalimumab [10, 11] . Here, we report on a patient who was diagnosed with intestinal BD despite being treated with the fully humanized TNF-α blocker (adalimumab) for underlying ankylosing spondylitis. This patient achieved and maintained clinical remission and complete mucosal healing through the addition of a steroid and azathioprine to the adalimumab regimen for 43 mo.
CASE REPORT
A 29-year-old male patient was hospitalized due to severe right lower quadrant abdominal pain for the preceding 15 d. He had experienced recurrent oral ulcerations and arthralgia for 15 years and had had an erythematous papule on his back for the past 2 years. He had undergone appendectomy for appendicitis 17 years ago. He was diagnosed with ankylosing spondylitis 2 years ago because of lower back and shoulder pain. He had taken salazopyrine 1000 mg for 2 mo and had been injected with infliximab for his ankylosing spondylitis for 9 mo (5 mg/kg intravenously at 0, 2 and 6 wk; 5 mg/kg intravenously every 8 wk). The oral ulcerations, arthralgias, and erythematous papule on his back had improved, but his back pain had not been improved at that time. Therefore, the infliximab had been switched to adalimumab (40 mg subcutaneously every 2 wk) since 10 mo ago. On physical examination at admission, he appeared acutely ill, and had a blood pressure of 120/70 mmHg, a pulse of 84 beats/min, a respiratory rate of 24 breaths/min, and a temperature of 36.5 ℃. The abdomen was flat with direct tenderness in the right lower quadrant. Bowel sounds were normal. The results of laboratory tests showed a white blood cell count (WBC) of 20930/mm 3 ; hemoglobin, 13.9 g/dL; hematocrit, 41.7%; platelet count, 282000/mm 3 ; total protein, 7.2 g/dL; erythrocyte sedimentation rate increased to 33 mm/h; and C-reactive protein increased to 111 mg/L. A colonoscopy performed on admission showed a well-demarcated, large, deep ulcer with an exudate, mucosal edema, and erythema at the terminal ileum ( Figure 1A activity [12] . Subsequently, the patient was treated with conventional medical therapy, including azathioprine 150 mg and 5-aminosalicylate (5-ASA, Pentasa) 3000 mg/d. His abdominal pain seemed to decrease after 10 d. However, the patient's severe right lower quadrant abdominal pain recurred after one month. The DAIBD score at the time of recurrent abdominal pain was 80, again reflecting severe disease activity [12] . In the early stages of treatment, clinical remission could not be obtained through combination therapy with azathioprine and 5-ASA. Thus, at the time of abdominal pain recurrence, intravenous hydrocortisone (300 mg/d) was administrated. Then the abdominal pain was improved 2 d after steroid injection. Intravenous hydrocortisone was slowly tapered to oral prednisolone for 2 mo. Finally, DAIBD score was 10. A follow-up colonoscopy after 36 mo demonstrated that the ulcer at the terminal ileum was replaced by normal mucosa (Figure 1D -F) with complete mucosal healing. Combination therapy with azathioprine, 5-ASA and adalimumab was continued for 43 mo with clinical and endoscopic remission.
DISCUSSION
We reported on a 29-year-old man with BD and ankylos-ing spondylitis who developed intestinal BD despite continuous use of adalimumab. We treated this patient with intravenous steroids to induce clinical remission and with azathioprine and 5-ASA for maintenance of remission. This case is unique in two ways. First, the terminal ileal ulcer characteristic of intestinal BD appeared while the patient was receiving adalimumab for ankylosing spondylitis. Second, mucosal healing was achieved and maintained through combination therapy with azathioprine and 5-ASA after induction of remission with intravenous steroids.
Conventional therapies such as mesalamine, corticosteroids, immunosuppressive agents, thalidomide, bowel rest, and total parenteral nutrition have been used in the treatment of intestinal BD [13] . However, in patients with intestinal BD unresponsive to conventional therapies, TNF-α blockers have been shown to improve symptoms [12] . Both infliximab and adalimumab can be used for treatment of intestinal BD because they are similar active biologics, monoclonal antibodies to TNF-α [10, 11, 14] . There has been no data available regarding the comparative efficacy of infliximab and adalimumab in intestinal BD. In Table 1 there have been many publications reporting on the effectiveness of infliximab [4] [5] [6] [7] [8] [9] . However, there have been only a few reports of the efficacy of adalimumab 5391
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